Regenxbio IncNASDAQ:RGNX
- LAST PRICE10.9258
- TODAY'S CHANGE (%)0.2458 (2.3015%)
- Bid / Lots10.9200/ 2
- Ask / Lots10.9400/ 1
- Open / Previous Close10.8700 / 10.6800
- Day Range
- 52 Week Range
- Volume155,861
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RGNX |
|---|---|---|
| 09:32 ET | 3724 | 10.87 |
| 09:36 ET | 252 | 10.82 |
| 09:38 ET | 600 | 10.88 |
| 09:39 ET | 300 | 10.93 |
| 09:41 ET | 100 | 10.98 |
| 09:43 ET | 400 | 10.985 |
| 09:45 ET | 100 | 10.98 |
| 09:48 ET | 5800 | 10.99 |
| 09:50 ET | 4383 | 10.95 |
| 09:52 ET | 100 | 10.87 |
| 09:54 ET | 5900 | 10.97 |
| 09:56 ET | 300 | 10.98 |
| 09:57 ET | 1069 | 10.93 |
| 09:59 ET | 2100 | 10.925 |
| 10:01 ET | 2564 | 11.115 |
| 10:03 ET | 3446 | 11.115 |
| 10:06 ET | 200 | 11.085 |
| 10:08 ET | 200 | 11.05 |
| 10:10 ET | 400 | 11.075 |
| 10:12 ET | 400 | 11.09 |
| 10:14 ET | 845 | 11.08 |
| 10:15 ET | 2500 | 11.03 |
| 10:17 ET | 200 | 11.03 |
| 10:19 ET | 507 | 11.04 |
| 10:21 ET | 1100 | 10.98 |
| 10:24 ET | 100 | 11.035 |
| 10:26 ET | 900 | 11.07 |
| 10:28 ET | 600 | 11.065 |
| 10:30 ET | 501 | 11.05 |
| 10:32 ET | 600 | 11.04 |
| 10:33 ET | 3150 | 11.035 |
| 10:35 ET | 400 | 11.035 |
| 10:37 ET | 600 | 11.03 |
| 10:39 ET | 4909 | 11.14 |
| 10:42 ET | 300 | 11.14 |
| 10:44 ET | 200 | 11.14 |
| 10:46 ET | 514 | 11.15 |
| 10:48 ET | 900 | 11.19 |
| 10:50 ET | 944 | 11.18 |
| 10:51 ET | 405 | 11.19 |
| 10:53 ET | 2400 | 11.165 |
| 10:55 ET | 400 | 11.165 |
| 10:57 ET | 7372 | 11.095 |
| 11:00 ET | 300 | 11.11 |
| 11:02 ET | 598 | 11.1 |
| 11:04 ET | 1200 | 11.1008 |
| 11:06 ET | 300 | 11.115 |
| 11:08 ET | 257 | 11.15 |
| 11:09 ET | 858 | 11.13 |
| 11:11 ET | 600 | 11.15 |
| 11:13 ET | 100 | 11.16 |
| 11:15 ET | 500 | 11.15 |
| 11:18 ET | 400 | 11.15 |
| 11:20 ET | 343 | 11.191591 |
| 11:22 ET | 200 | 11.2 |
| 11:24 ET | 1490 | 11.19 |
| 11:26 ET | 653 | 11.16 |
| 11:31 ET | 100 | 11.18 |
| 11:33 ET | 200 | 11.18 |
| 11:36 ET | 200 | 11.2 |
| 11:38 ET | 1000 | 11.18 |
| 11:40 ET | 1100 | 11.13 |
| 11:42 ET | 500 | 11.125 |
| 11:44 ET | 200 | 11.155 |
| 11:49 ET | 700 | 11.19 |
| 11:51 ET | 1370 | 11.16 |
| 11:54 ET | 730 | 11.16 |
| 11:56 ET | 600 | 11.14 |
| 11:58 ET | 200 | 11.13 |
| 12:00 ET | 200 | 11.13 |
| 12:02 ET | 6106 | 11.1 |
| 12:03 ET | 900 | 11.09 |
| 12:05 ET | 500 | 11.07 |
| 12:07 ET | 489 | 11.06 |
| 12:09 ET | 800 | 11.05 |
| 12:12 ET | 800 | 11.045 |
| 12:14 ET | 236 | 11.045 |
| 12:16 ET | 700 | 10.99 |
| 12:18 ET | 4232 | 10.9301 |
| 12:20 ET | 261 | 10.9304 |
| 12:21 ET | 415 | 10.95 |
| 12:23 ET | 850 | 10.93 |
| 12:25 ET | 400 | 10.93 |
| 12:27 ET | 305 | 10.95 |
| 12:30 ET | 1140 | 10.95 |
| 12:32 ET | 1300 | 10.93 |
| 12:34 ET | 1700 | 10.935 |
| 12:36 ET | 500 | 10.92 |
| 12:38 ET | 400 | 10.935 |
| 12:39 ET | 1724 | 10.94 |
| 12:41 ET | 610 | 10.92 |
| 12:45 ET | 100 | 10.935 |
| 12:48 ET | 615 | 10.94 |
| 12:50 ET | 1100 | 10.92 |
| 12:52 ET | 100 | 10.925 |
| 12:54 ET | 1000 | 10.9258 |
Sep 23, 2024
REGENXBIO to Participate in Chardan's 8th Annual Genetic Medicines Conference, from 4:05PM ET on Monday Sep 23, 2024 by Dow Jones
4:05PM ET on Monday Sep 23, 2024 by Dow Jones
Sep 17, 2024
DJ Regenxbio Names Chan Finance Chief as Vasista Departs, from 7:53AM ET on Tuesday Sep 17, 2024 by Dow Jones
7:53AM ET on Tuesday Sep 17, 2024 by Dow Jones*DJ REGENXBIO Appoints Mitchell Chan As Chief Financial Officer >RGNX, from 7:05AM ET on Tuesday Sep 17, 2024 by Dow Jones
7:05AM ET on Tuesday Sep 17, 2024 by Dow JonesREGENXBIO Appoints Mitchell Chan as Chief Financial Officer, from 7:05AM ET on Tuesday Sep 17, 2024 by Dow Jones
7:05AM ET on Tuesday Sep 17, 2024 by Dow Jones
Sep 4, 2024
DJ REGENXBIO Price Target Maintained With a $39.00/Share by HC Wainwright & Co., from 12:46PM ET on Wednesday Sep 04, 2024 by Dow Jones
12:46PM ET on Wednesday Sep 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Regenxbio Inc | 527.8M | -2.1x | --- |
Urogen Pharma Ltd | 537.0M | -3.9x | --- |
Y-mAbs Therapeutics Inc | 571.4M | -23.0x | --- |
Alector Inc | 468.1M | -2.7x | --- |
SAGE Therapeutics Inc | 437.7M | -1.0x | --- |
Grail Inc | 422.3M | -0.1x | --- |
Company Information
REGENXBIO Inc. is a clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. The Company has developed a pipeline of gene therapy programs using its proprietary adeno-associated virus (AAV) gene therapy delivery platform (NAV Technology Platform) to address genetic diseases. The Company is focused on its internal development pipeline in three areas: retinal, neuromuscular and neurodegenerative diseases. Its investigational AAV therapeutics include ABBV-RGX-314, RGX-202 and RGX-121. It is developing ABBV-RGX-314 in collaboration with AbbVie to treat large patient populations impacted by wet age-related macular degeneration, diabetic retinopathy (DR) and other chronic retinal diseases characterized by loss of vision. It is developing RGX-202 to treat Duchenne muscular dystrophy (Duchenne). The Company is developing RGX-121 to treat Mucopolysaccharidosis type II (MPS II), a progressive, neurodegenerative lysosomal storage disorder.
Contact Information
- Headquarters
- 9804 Medical Center DriveROCKVILLE, MD, United States 20850
- Phone
- 240-552-8181
- Fax
- 302-655-5049
Executives
- Chairman of the Board
- Kenneth Mills
- President, Chief Executive Officer, Director
- Curran Simpson
- Chief Financial Officer, Executive Vice President, Principal Accounting Officer
- Mitchell Chan
- Executive Vice President, Chief Scientific Officer
- Olivier Danos
- Executive Vice President, Chief Legal Officer
- Patrick Christmas
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $527.8M |
|---|---|
Revenue (TTM) | $89.0M |
Shares Outstanding | 49.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.22 |
EPS | $-5.27 |
Book Value | $7.08 |
P/E Ratio | -2.1x |
Price/Sales (TTM) | 5.9 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -279.37% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
